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Abstract 
 
A core pathological feature of AD is the over-production of reactive oxygen species (ROS), 
which mediate oxidative stress in the brain. Peroxisomes play a crucial role in mitigating ROS 
accumulation due to the presence of catalase, an antioxidant enzyme found within the organelle. 
As the brain ages, progressive dysfunction of peroxisomes and decreased localization of catalase 
into the organelle contributes to elevated ROS. A suitable therapy to address the increased 
accumulation of ROS in AD has yet to be identified. Our team has engineered a recombinant 
derivative of the antioxidant enzyme catalase (CAT-SKL) that specifically targets peroxisomes, 
thereby providing powerful organelle-based antioxidant and anti-inflammatory effects. In the 
present study, we aimed to (i) establish the packaging CAT-SKL into macrophage-derived 
exosomes — endogenous membrane vesicles for the transport of proteins between cells — to 
effectively target our therapeutic to cells undergoing oxidative stress while minimizing 
degradation in the bloodstream, (ii) determine the safety and biodistribution in vivo, and (iii) assess 
the protective effects of prophylactic intranasal administration of exosomes loaded with CAT-SKL 
(exoCAT-SKL). CAT-SKL was packaged into macrophage-derived exosomes via sonication, and 
loaded exosomes were purified using size exclusion chromatography or ultracentrifugation. Male 
and female, control, and 3xTG AD transgenic mice were intranasally administered exoCAT-SKL, 
and tissues of interest were investigated. The diffuse labelling of CAT- SKL in these mice's brains 
supports the intranasal administration of exosomes as an effective delivery method to bypass issues 
surrounding bioavailability, antigenicity, and the blood-brain barrier. Histopathological 
assessments of the brain and off-target tissue demonstrated no toxicity. Further behavioural and 
immunohistochemical analysis is required to determine whether exoCAT-SKL can prevent and 
ameliorate pathological and behavioural outcomes in 3xTG AD mice. 
 
 
 
Keywords: Alzheimer’s disease, Oxidative Stress, Drug delivery and toxicology, Exosomes, 
Therapeutic antioxidants, Catalase 
 
 
 
 
 
 
 
 
 
 iii 
Lay summary 
This project investigated the use of nanosized vesicles called exosomes to carry and deliver 
CAT-SKL, an antioxidant molecule, into a preclinical transgenic mouse model of Alzheimer’s 
disease (AD). Human patients with AD demonstrate progressive dysfunction of peroxisome-
mediated lipid oxidation leading to excessive accumulation of reactive oxygen species (ROS). 
CAT-SKL specifically targets these peroxisomes and provides antioxidant, anti-inflammatory and 
anti-ageing effects. Intranasal administration of CAT-SKL loaded exosomes can penetrate the 
brain, potentially preventing and ameliorating pathological, biochemical, and behavioural 
outcomes. This project also provided further validation for the use of nanoparticles to deliver 
therapeutics to the brain. 
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1.1 Alzheimer’s disease  
Alzheimer's disease (AD) is a neurodegenerative disorder that causes a progressive decline 
in a person's cognitive and behavioural abilities (Neugroschl and Wang, 2011). AD has a 
devastating impact not only on the diagnosed individual but also on caregivers and healthcare 
systems (Koca, Taşkapilioğlu and Bakar, 2017). In Canada, over half a million people are living 
with AD, and the number of AD cases is expected to double in the next 15 years (Alzheimer's 
Disease International, 2019). Globally, in 2006, an estimated 26.6 million people were living with 
AD, and over 106 million cases are projected by 2050 (Brookmeyer et al., 2007). Symptoms of 
AD begin with confusion, amnesia, and progress to severe cognitive impairments such as memory 
and language deficits, and executive dysfunction (Förstl and Kurz, 1999; Humbert et al., 2010). 
Eventually, the deterioration and loss of critical bodily functions such as the ability to swallow 
cause severe complications and lead to death (Zanetti, Solerte and Cantoni, 2009). This 
progression is variable as the typical life expectancy following diagnosis is between 3 and 9 years. 
Currently, Canada is ill-equipped to manage the growing costs and lacks the infrastructure to 
manage this public health crisis (Chambers, Bancej and Mcdowell, 2016). Understanding the 
etiology and pathology of AD are essential first steps in combating the AD epidemic and reducing 
the burden to healthcare resources. 
AD can be categorized into early-onset and late-onset AD. Two universal hallmark 
pathologies of the AD brain are extracellular β-amyloid (Aβ) plaque deposition and intracellular 
aggregates of tau protein forming neurofibrillary tangles. As AD progresses, these two pathologies 
are strongly linked to neuroinflammation, the loss of neurons and synapses, as well as the 
enlargement of ventricles due to whole brain atrophy (Perl, 2010). Several genetic mutations have 
been identified as the cause of the early-onset autosomal dominant form of AD. These mutations 
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are found in the amyloid precursor protein (APP), presenilin 1 (PS1) and presenilin 2 (PS2) 
(Piaceri, Nacmias and Sorbi, 2013). In particular, APP, PS1, and PS2 mutations affect the 
processing of APP at γ-secretase or β-secretase cleavage sites. These mutations result in an 
increased production of Aβ peptides leading to an increased accumulation of amyloid plaques 
(Bhadbhade and Cheng, 2012; Kelleher and Shen, 2017). The majority of AD cases are not 
categorized as early-onset. It is estimated that up to 70% of cases are of the late-onset category 
(Piaceri, Nacmias and Sorbi, 2013). The most prevalent genetic risk factor for developing late-
onset AD is the apolipoprotein E (ApoE) 4 allele (Vanitallie, 2013; Safieh, Korczyn and 
Michaelson, 2019). ApoE plays an essential role in cholesterol transport and regulating lipid 
metabolism in the brain (Huang and Mahley, 2014). Possession of the ApoE 4 allele results in 
reduced Aβ clearance by the glymphatic system and astrocytes, one of the brain's glial cell types. 
As such, individuals homozygous for the ApoE 4 allele have up to 12 times the risk of developing 
AD (Michaelson, 2014; Fernandez et al., 2019). The etiology of AD remains convoluted due to 
the complexity of the disease as it involves a combination of protein misfolding and aggregation, 
neuroinflammation, and oxidative stress, amongst other environmental factors (Jiang et al., 2013). 
 Although genetics convey additional risks for affected individuals, the most significant 
known risk factor for AD is age (Guerreiro and Bras, 2015). The majority of AD patients are older 
than 65, with a higher incidence among older populations. Suggested practices by the National 
Institute of Health to prevent AD or delay the age of onset include: managing comorbidities such 
as diabetes and high blood pressure, increasing physical activity, maintaining a healthy balanced 
diet, and staying cognitively stimulated (National Institute of Health, 2018). These 
nonpharmacologic measures are also crucial in the management of symptoms as a cure for AD 
does not yet exist (Dharmarajan and Gunturu, 2009). Available treatments that target Aβ 
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production, aggregation, or clearance have not led to curative clinical outcomes (Yiannopoulou 
and Papageorgiou, 2013; Mehta et al., 2017). The most common drug option, acetylcholinesterase 
inhibitors, have been shown to slow the progression of the disease but often lead to off-target 
toxicity such as hepatotoxicity and adverse gastrointestinal symptoms (Ali et al., 2015). Other 
drugs such as N-Methyl-D-aspartate inhibitors are better tolerated however are typically prescribed 
for advanced stage AD with modest benefits in patients (Olivares et al., 2013). Developing 
potential medications that are both safe and effective requires further knowledge of how AD 
disrupts the brain.  
 
1.2 Anatomical brain areas associated with AD  
As AD progresses, different areas of the brain are affected, highlighting the connections 
between anatomical and cognitive changes (Raskin et al., 2015). In earlier stages of the disease, 
cells of the hippocampus begin to degenerate, causing deficits in memory and learning. Significant 
reductions of neurons are seen in the CA1 and less so in CA3 hippocampal areas of patients with 
AD (Padurariu et al., 2012), which may partially explain the loss of memory seen in AD patients. 
The hippocampus is an especially vulnerable and essential brain area strongly tied to the cognitive 
impairments accompanied with AD (Halliday, 2017).  
In the moderate AD stage, cerebral cortical atrophy occurs, causing severe behavioural 
deficits and the inability to perform simple tasks (Bakkour et al., 2013). Post-mortem examination 
of AD brains reveals a reduction in total brain size and weight, with widened sulci indicating the 
loss of cortical interneurons and neurotransmitter pathways (Whitwell, 2010). In human and rodent 
models of AD, a loss of cholinergic neurons is observed in the basal forebrain, while noradrenergic 
degeneration is observed in the locus coeruleus (Mufson et al., 2008). While this phenomenon is 
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observed in the moderate stage for humans, it is not replicated in rodent models of AD until later 
stages of the disease. Instead, preclinical moderate stage AD mouse models feature 
neuroinflammation marked by microgliosis, astrocytosis, and deposits of amyloid plaques (Saito 
and Saido, 2018).  
Findings in rodents show that early-stage neuroinflammation and white matter etiologies 
contribute to AD progression in addition to grey matter etiologies. In particular, white matter 
inflammation and demyelination have been reported in the corpus callosum and the internal 
capsule preceding Aβ plaques, perhaps driving Aβ production (Raj et al., 2017). Developing drugs 
to target the hippocampus and white matter inflammation early on in AD progression may prevent 
or reduce cognitive decline.  
 
1.3 Beta-amyloid, amyloid cascade hypothesis and neuroinflammation 
The amyloid cascade hypothesis has been the most prominent AD research hypothesis 
since the early 1990s (Hardy and Allsop, 1991; Selkoe, 1991; Hardy and Higgins, 1992; Ricciarelli 
and Fedele, 2017). The hypothesis posits that excessive Aβ causes AD and triggers a cascade of 
downstream symptoms and pathologies such as cognitive decline, progressive neuronal injury, 
neuroinflammatory responses, and oxidative injury (Barage and Sonawane, 2015). Aβ is derived 
from APP, which is ubiquitously expressed but predominantly in the central nervous system (CNS) 
(Puig and Combs, 2013). APP is a highly conserved transmembrane protein; however, the exact 
function of APP is not fully understood. It is accepted that it plays a role in cell growth, cell 
survival, and synapse physiology (Bhadbhade and Cheng, 2012). The production of Aβ is a normal 
cellular process and begins with sequential cleavage of APP by two intramembranous 
endoproteases, β-secretase and γ-secretase. β-secretase cleaves APP into a protein that is 99 amino 
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acids in length, and γ-secretase subsequently cleaves the protein at the γ-cleavage site to 38 - 42 
amino acids (Chow et al., 2010; Macleod et al., 2015). A third endoprotease, α-secretase, can also 
cleave APP; however, the resulting peptide (sAPP- α) does not lead to Αβ formation (Zhang et al., 
2011). Ninety-percent of the cleaved APP is 40 amino acids in length (Aβ40), and the less abundant 
cleaved APP is 42 amino acids in length (Aβ42) (Qiu et al., 2015). The two isoforms of Aβ differ 
by two amino acids, isoleucine and alanine, with Aβ42 more highly related to AD pathogenesis 
compared to Aβ40. Aβ42 demonstrates increased aggregation and fibril formation, which 
contribute to amyloid plaques formation (Cline et al., 2018). Aβ42 has also been reported to have 
higher cellular toxicity, and clinical experiments suggest mutations causing AD result in an 
increase in the Aβ42 to Aβ40 ratio (Lehmann et al., 2018). Both isoforms of Aβ can be found in 
the cerebrospinal fluid (CSF) with 50-70% in the form of Aβ40 and roughly 10% as Aβ42 in 
healthy adults. Aβ37, Aβ38, Aβ39, and Aβ43 isoforms make up the remaining Aβ found in the 
CSF (Qiu et al., 2015). An increased ratio of CSF Aβ42 to Aβ40 in combination with CSF 
concentrations of tau species has been used as a diagnostic tool of AD (Hansson et al., 2019).  
Several mechanisms exist to catabolize Aβ42 for degradation or transport out of the CNS. 
Enzymes such as neprilysin and insulin degrading enzyme play essential roles in the extracellular 
degradation of Aβ while transport proteins called low-density lipoprotein receptor-related protein 
1 are responsible for transcellular transport of Aβ across the blood-brain-barrier (BBB) (Deane et 
al., 2009; Grimm et al., 2013). The amyloid cascade hypothesis proposes that neurodegeneration 
arises when Aβ is overproduced, and the clearance and degradation are reduced, causing the 
buildup of Aβ (Barage and Sonawane, 2015).  
The hydrophobic nature of Aβ42 enables the formation of β sheet protein structures, and 
other structures such as fibrils and oligomers (Baldassarre et al., 2017). Aβ oligomers are reported 
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to be more toxic than Aβ fibrils and cause oxidative damage, cell membrane disruption, and induce 
neural cell apoptosis pathways (Verma, Vats and Taneja, 2015; Sengupta, Nilson and Kayed, 
2016). In addition, Aβ triggers the activation of inflammatory responses marked by reactive 
microglia activation and reactive astrocytosis (Hensley, 2010). Microglia and astrocytes respond 
to insults caused by Aβ by transitioning from a ramified form to an active phagocytic form and 
migrating to the site of injury. The number of activated microglia and astrocytes has been shown 
to increase in relation to the amount of Aβ plaques (Bolmont et al., 2008). Scavenger receptors on 
microglia and its phagocytic nature allow for modest Aβ engulfment, but the activated microglia 
phenotype is accompanied by the release of pro-inflammatory cytokines and ROS (Doens and 
Fernández, 2014). Aβ deposits are difficult to remove, and chronic microglial activation as seen in 
AD leads to a 'frustrated phagocytosis' phenotype, causing an extended release of inflammatory 
molecules such as interleukin-1β, interleukin-6, and tumour necrosis factor-α (Majerova et al., 
2014; Wang et al., 2015). This phenomenon causes a toxic environment for neurons and also leads 
to neurotoxic injuries such as demyelination, synaptic dysfunction, and ultimately neuron death 
(Lull and Block, 2010). Therefore, exploring neuroinflammation is a promising strategy that may 
lead to novel approaches and ameliorate the burden of AD. 
 
1.4 Reactive oxygen species and oxidative stress in Alzheimer’s disease 
 
Oxidation and reduction (redox) reactions in living organisms are utilized in fundamental 
processes and are necessary for overall health. An unavoidable consequence of redox reactions is 
the production of ROS (Zuo et al., 2015). ROS is an umbrella term that includes active oxygen-
containing compounds such as hydrogen peroxide (H2O2), superoxide anion (O2- ), hydroxyl 
radical (OH-), amongst other radicals. ROS is primarily produced in the mitochondria through the 
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electron transport chain and the oxidative phosphorylation pathway (Ray, Huang and Tsuji, 2012). 
In particular, H2O2 is continuously produced by the mitochondria and accounts for 40% of the 
H2O2 in the cytosol (Boveris and Cadenas, 2001). Compared to other ROS, H2O2 is a stable 
molecule that can diffuse easily between cells and react with free metals (Groeger, Quiney and 
Cotter, 2009). The Fenton reaction occurs when H2O2 reacts with iron or copper to produce the 
damaging hydroxyl radical (Winterbourn, 1995). 
 
Fe2+ + H2O     ® Fe3+ + [H2O2-]     ® OH + OH- 
 
ROS are signalling messengers that play a role in normal cellular function (Dröge, 2002), 
but become problematic when they are chronically present. ROS modulate cell cycle pathways 
and maintain the balance between cell proliferation and apoptosis at normal levels (Finkel, 2011). 
ROS also play an important role in the immune system as cells utilize ROS to undergo the 
phagocytosis process and fight against foreign bodies (Dupré-Crochet, Erard and Nüβe, 2013). 
Neutrophils, monocytes, macrophages and microglia are significant cellular sources of 
ROS.  These cells utilize cellular enzymes such as nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase to secrete ROS and serve as both a protective and inflammatory mechanism 
(Haslund-Vinding et al., 2017). Toll-like receptor-4 on the surface of microglia is activated by the 
binding of foreign bodies to NADPH oxidase triggering downstream ROS production to 
breakdown pathogens (Fiebich et al., 2018). However, ROS can be extremely harmful if produced 
in excess of normal physiologic levels (Zuo et al., 2015). Downstream effects due to the 
overproduction of ROS include lipid peroxidation, nucleic acid damage, protein oxidation, and 
enzyme inhibition, all leading to cellular dysfunction and cell death (Mylonas and Kouretas, 1999; 
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Cadet and Richard Wagner, 2013; Sharman, 2016). Lipid peroxidation occurs when ROS targets 
polyunsaturated fatty acids of membrane phospholipids in the brain (Sultana, Perluigi and 
Butterfield, 2013). These reactions lead to the production of highly reactive aldehydes such as 4-
hydroxy-2-nonenal and malondialdehyde. Reactive aldehydes are strong electrophiles and react 
with amino acids and nucleic acids, leading to the inhibition of DNA, RNA, cell membrane 
function, and protein synthesis (Matveychuk et al., 2011).  
Antioxidants are endogenous molecules that function to counteract free radicals and 
neutralize oxidants by breaking them down into less reactive molecules (Pham-Huy, He and Pham-
Huy, 2008). However, excessive ROS levels can overwhelm the body’s antioxidant mechanisms, 
resulting in oxidative stress. Increased oxidative stress is linked to ageing and disease  (Liguori et 
al., 2018). The over-production of ROS can be attributed to several mechanisms such as 
mitochondrial electron-transport chain dysfunction, overwhelmed antioxidant mechanisms, 
microglia activation pathways, amyloid deposition, and metal abnormalities (Valko et al., 2007; 
Su et al., 2008). These primary sources of ROS imbalances have been implicated in both the 
pathogenesis of AD as well as an outcome of the disease (Wang et al., 2014; Manoharan et al., 
2016). Aβ42 induces oxidative stress in the brain by binding with transition metal ions such as iron 
and copper generating H2O2  and other hydroxyl radicals (Huang et al., 1999). Markers of 
increased lipid peroxidation have also been correlated with amyloid plaques deposition (Praticò et 
al., 2001). More research is required to characterize oxidative sources and the cellular 
consequences of excessive ROS. This is of particular importance since the regulation of ROS 
through cellular antioxidant systems is crucial for maintaining cell viability and ultimately organ 
function in patients with AD. 
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1.5 Peroxisomes and cellular mechanisms of ROS mitigation  
Mammalian peroxisomes are essential organelles that perform oxidation reactions involved 
in the breakdown of amino and fatty acids to produce metabolic energy (Cooper, 2000). 
Peroxisomes are a significant source of oxidative metabolism comprising up to 20% of total 
cellular oxygen consumption and oxidative stress (Wanders, Waterham and Ferdinandusse, 2016). 
Within the nervous system, peroxisomes are found in all neural cell types such as neurons, 
microglia, astrocytes, and oligodendrocytes.  Peroxisomes of the nervous system are involved in a 
variety of catabolic and anabolic reactions, including the biosynthesis of lipids, critical for the 
formation of myelin and membrane processes of oligodendrocytes (Baes and Aubourg, 2009). A 
harmful consequence of these oxidation reactions is the production of H2O2. The primary source 
of H2O2 produced in peroxisomes occurs through the β-oxidation of fatty acids  (Bonekamp et al., 
2009). This catabolic process oxidizes fatty acids into acetyl-CoA subunits; however, the high-
energy electrons that are generated are not coupled to a respiratory chain destined for ATP 
synthesis like those seen in the mitochondria. Instead, these electrons are coupled to oxygen 
reduction reactions to form reactive H2O2 in turn upsetting the cellular redox balance, and 
damaging DNA, proteins and lipids (Mylonas and Kouretas, 1999).  
Peroxisomes contain many antioxidant enzymes that combat the effect of ROS, including 
superoxide dismutase, peroxiredoxin, epoxide hydrolase, and catalase (Fransen et al., 2012). 
Catalase is a 62 kDa enzyme that plays a critical protective role because it catalyzes H2O2 back 
into water and oxygen (Schrader and Fahimi, 2006). 
  
   2 H2O2  ®     2 H2O + O2    
 
Catalase 
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 Like all other peroxisomal matrix proteins, endogenous catalase is transcribed in the 
cytosol and targeted to peroxisomes through the use of 4 amino acid residues at its carboxy 
terminus, lysine-alanine-asparagine- leucine (-KANL), making up a peroxisome-targeting signal 
sequence (PTS1) (Sheikh et al., 1998). The peroxisomal targeting signal type 1 receptor (PEX5p) 
recognizes the targeting sequence on catalase leading to internalization of the enzyme for 
H2O2  homeostasis (Terlecky, Koepke and Walton, 2006). These protective antioxidant systems 
can be overwhelmed by ageing, cellular disturbances and peroxisomal dysfunction.  
In cell culture models of ageing, the serial passaging of cells demonstrated decreased 
catalase import into peroxisomes resulting in increased oxidative stress and cell senescence 
(Koepke et al., 2007). Some diseases, such as the rare congenital Zellweger syndrome, are marked 
by PEX5p mutations leading to deficient catalase import and excessive H2O2 buildup (Berger et 
al., 2016). Peroxisomal dysfunction contributes to the pathogenesis of a variety of other diseases, 
including cancer, diabetes, and AD (Cipolla and Lodhi, 2017). It is clear that peroxisomes and 
catalase enzyme function as mediators of H2O2 metabolism. Additional research is required to 
understand how this peroxiosomal pathway can potentially contribute to AD prevention. The 
effectiveness of drugs that specifically target peroxisomes and H2O2 accumulation remains to be 
determined.  
 
1.6 Targeted antioxidant CAT-SKL 
One of the major limitation of endogenous catalase is that the residues that make up its 
PTS1 functionally deteriorate as cells age (Koepke et al., 2007). Due to this deterioration, strategies 
have been previously developed to improve the shuttling of catalase to peroxisomes. The 
engineered catalase (CAT-SKL, United States patents 7601366 and 8663630) used in this study 
 
 
 12 
replaces the -KANL terminus with a serine-lysine-leucine (-SKL) sequence to increase 
peroxisomal targeting, thereby allowing for higher enzymatic metabolism of H2O2 (Koepke et al., 
2007; Giordano et al., 2015; Nell et al., 2017). The -SKL sequence is a more efficient peroxisome 
targeting signal for importing proteins compared to the -KANL sequence and even functions when 
PEX5p receptors are mutated (Koepke et al., 2007). CAT-SKL is effective in mitigating oxidative 
stress in several in vitro and in vivo studies. Subcutaneous injections of CAT-SKL improved 
subnormal intraretinal uptake of manganese and reduced oxidative liver damage in diabetic mice 
(Giordano et al., 2015). CAT-SKL also protected against Aβ induced neurotoxicity and oxidative 
stress in cultured primary cortical/hippocampal neurons (Giordano et al., 2014; Nell et al., 2017). 
These pre-clinical studies suggest that CAT-SKL holds potential as a new therapeutic approach to 
address the increased accumulation of ROS in disorders such as Parkinson’s and AD (Valko et al., 
2007; Price, Terlecky and Kessel, 2009; Cipolla and Lodhi, 2017; Nell et al., 2017).  However, 
the use of therapeutic antioxidants such as CAT-SKL has been hindered by physiological barriers 
such as degradation of the antioxidant before reaching its cellular target (Moosmann and Behl, 
2002). In addition, exogenous CAT-SKL alone has not been shown to penetrate the BBB. 
Identifying a delivery system to effectively cargo CAT-SKL to the brain is essential to investigate 
its protective effects in neurodegenerative diseases. 
 
1.7 Blood-brain barrier and the intranasal delivery pathway – function and potential 
The BBB is a unique microvasculature system that supports the CNS allowing for strict 
regulation of transport of molecules between the blood and the brain. The restrictive nature of the 
BBB is due to its anatomical architecture. A monolayer of polarized endothelial cells makes up 
the walls of the blood vessels (Serlin et al., 2015). These cells are securely sealed to each other by 
 
 
 13 
a network of proteins, including claudins and occludins, to form tight junctions (Luissint et al., 
2012). Supporting connective tissue cells called pericytes on the abluminal (brain facing) surface 
wrap the endothelial cells and play a role in endothelial proliferation and migration (Liu et al., 
2012). Astrocytes extend their cellular processes to sheath the entire endothelial cell border to 
regulate the BBB permeability and blood flow. This barrier acts to protect the brain from foreign 
bodies and other circulating pathogens (Daneman and Prat, 2015). The breakdown of the BBB 
causes disease pathologies and is observed in severe neurological diseases such as Parkinson’s 
disease, amyotrophic lateral sclerosis and AD (Sweeney, Sagare and Zlokovic, 2018). Although 
the BBB serves a crucial function in maintaining the brain's protected environment, its selective 
nature can become a limiting factor when designing potential therapeutics. Therefore the BBB is 
a major barrier that must be addressed in order to evaluate the efficacy of candidate therapies 
(Ballabh, Braun and Nedergaard, 2004).  
One approach to penetrate the BBB in treating neurodegenerative diseases is to implement 
the intranasal delivery of therapeutics (Erdő et al., 2018). Intranasal delivery utilizes both 
intracellular and extracellular pathways to the brain. The extracellular route directly connects from 
the nasal cavity to the brain and begins with crossing the nasal epithelium. The nasal epithelium is 
composed of diverse cells connected by tight junctions more permissible than that of the BBB 
(Yang et al., 2017). Lipophilic molecules can freely pass through these tight junctions, while 
hydrophilic molecules diffuse through the tight junctions based on their size. Once the drug has 
passed through the nasal epithelium, drugs are transported through the subarachnoid space of the 
brain and directly into the CSF. The intracellular route employs the olfactory and trigeminal 
nerves. It begins with endocytosis of the drug by olfactory sensory cells and subsequent axonal 
transport to their synaptic clefts in the olfactory bulb. The drug is further exocytosed, and 
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surrounding neurons repeat the neuronal translocation to other brain regions. Extracellular 
transport of drugs is much faster than intracellular transport and is the main pathway used in 
intranasal administration (Crowe et al., 2018a). While the intranasal route offers direct and rapid 
access of lipophilic molecules to the brain, issues regarding the stability of drug delivery remain. 
Targeting exogenous CAT-SKL through the nasal epithelium is impeded by protein degradation 
and the enzymes' hydrophilic outer surface (Domínguez, Sosa-Peinado and Hansberg, 2010; 
Pharmaceu Sci, Shah and Shao, 2017). The use of a lipophilic nanodelivery system that can protect 
CAT-SKL from degradation would allow for both efficient and targeted delivery of CAT-SKL to 
the brain (Li et al., 2017).  
 
1.8 Exosomes and their potential as therapy delivery tools 
Recent research into extracellular vesicles has garnered much attention and suggests a more 
significant physiological role than previously recognized. Almost all eukaryotic cells produce 
extracellular vesicles as a method of cell-to-cell communication (Tetta et al., 2013). Extracellular 
vesicles carry biological cargo, including proteins, and nucleic acids, which are often taken up by 
surrounding cells or transported through the circulatory system to distant cells (Margolis and 
Sadovsky, 2019).  Proteins and nucleic acids released from exosomes are able to carry out various 
functions such as modulating cellular function and gene expression (Yáñez-Mó et al., 2015; Iraci 
et al., 2016; Jiang and Gao, 2017).  
Exosomes are unique, nanosized extracellular vesicles, ranging from 30 nm to 150 nm in 
size (Théry et al., 2006). Exosomes originate from endosomes, which are internal invaginations 
(endocytosis) of the cell plasma membrane (Zhang et al., 2019). Endosomes undergo a maturation 
process from early through to late endosomes via interactions with the Golgi complex, where they 
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become increasingly acidic. During the late endosome stage, intraluminal vesicles form, and the 
late endosome migrates towards the plasma membrane (Scott, Vacca and Gruenberg, 2014). These 
intraluminal vesicles are contained within the late endosome until fusion occurs between the late 
endosome membrane and the plasma membrane, where they are subsequently released as 
exosomes into the extracellular space. Alternatively, exosomes can be transported for degradation 
in lysosomes before reaching the plasma membrane (Zhang et al., 2019). Exosome membranes 
have similar bilipid composition to that of the plasma membrane with additional lipids added from 
the Golgi complex. The enriched lipid composition of exosomes increases their stability during 
transport and allows for passage through membranes such as the BBB (Li et al., 2017). Once an 
exosome reaches its target cell, it can be internalized by several potential mechanisms, including 
receptor-dependant binding, direct fusion, and phagocytosis (McKelvey et al., 2015). 
 The innate ability of exosomes to permeate biological barriers with low immunogenicity 
and toxicity while acting as agents of cellular communication offers a potential strategy to deliver 
biologics of interest into cells (Barile and Vassalli, 2017; Jiang and Gao, 2017). Several methods 
have been successfully implemented to load exogenous cargo into exosomes allowing for the 
targeted cellular delivery (Zhuang et al., 2011; Tetta et al., 2013; Qu et al., 2018; Pomatto et al., 
2019; Zhang et al., 2019). Low loading capacity has been demonstrated from the passive 
incubation of exosomes with the selected cargo. Hydrophobic drugs can diffuse through the lipid 
membrane of exosomes along the concentration gradient (Zhuang et al., 2011; Haney et al., 2015). 
Other passive techniques include treating cells with drugs and collecting their secreted exosomes 
loaded with the drug (Pascucci et al., 2014). Mechanical methods have also been implemented to 
load exosomes actively. Haney et al. demonstrated that the permeabilization of macrophage-
derived exosomes with saponin and sonication techniques provide high loading efficiency (Haney 
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et al., 2015). In addition, techniques such as electroporation, freeze-thaw cycles, membrane 
permeabilizers have been used to load exosomes with small drug molecules and miRNA (Luan et 
al., 2017; Pomatto et al., 2019).  
The biodistribution of systemically administered exogenous exosomes is similar to other 
therapeutics such that accumulation primarily occurs in the liver, kidney, and spleen. Exosomes 
have low immunogenicity and are efficiently excreted in the bile, renal system, and circulating 
phagocytic cells (Lai et al., 2014). In vivo neuroimaging studies using nanoparticle tracking 
technology have indicated that intranasal administration of exosomes efficiently penetrates the 
BBB and demonstrates superior brain accumulation compared to intravenous administration 
(Betzer et al., 2017). Zhuang et al. showed that intranasal administration of exosomes loaded with 
curcumin was up-taken by microglia while Haney et al. demonstrated that intranasal administration 
of exosomes loaded with catalase can effectively be delivered to neurons of mice as a 
neuroprotective method against Parkinson’s disease (Zhuang et al., 2011; Haney et al., 2015). 
Using macrophage-derived homologous exosomes of the same species as a delivery tool allows 
for biologics to overcome barriers such as biodistribution, antigenicity, and the BBB. These 
physiological hurdles have historically limited the therapeutic potential of proteinaceous reagents 
in neurodegenerative diseases such as AD. 
 
1.9 3xTG AD mouse model 
There are numerous animal models to choose from to study AD, each with a distinct set of 
AD pathophysiology. Most commonly used are transgenic rodents that foster characteristic AD-
related genetics. These genes are either disease-causing or serve as increased risk factors and 
include APP, tau, PS1, and ApoE (Hall and Roberson, 2012). Although any single model cannot 
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completely recapitulate AD pathology, mouse models conserve many of the mammalian genetic 
and physiological characteristics observed in humans. Mice are a cost-effective reductionist 
system that enables experimental manipulation in preclinical testing to develop new drugs 
(Perlman, 2016). The model selected for this thesis was the 3xTG-AD mouse line, which combines 
three mutant transgenes. The first is the human APP gene carrying the Swedish mutation. The APP 
Swedish double mutations cause two amino acid substitutions (lysine to asparagine and methionine 
to leucine) adjacent to the β-secretase site of APP. These mutations have been reported to increase 
total Aβ levels (Haass et al., 1995). Mice carrying the APP Swedish mutations such as the 3xTG-
AD mouse line accumulate high levels of both soluble and insoluble Aβ and develop amyloid 
pathology (Giménez-Llort et al., 2013). The second mutation involves the M146V mutation of 
presenilin, a gene that encodes proteins required for the catalytic subunit of γ-secretase. Two 
hypotheses surround how presenilin mutations lead to neurodegeneration and cognitive 
impairments in AD. The amyloid hypothesis proposes that presenilin mutations increase the 
production of Aβ42 or the Aβ42 to Aβ40 ratio, thus leading to increased amyloid plaque 
deposition. The presenilin hypothesis proposes that presenilin mutations cause the loss of 
presenilin function and reduces essential functions in learning, memory and neuronal survival 
(Elder et al., 2010; Kelleher and Shen, 2017) The third and final mutation characterizing this 
mouse model is the P301L mutation of human tau.  (Sterniczuk et al., 2010). Tau mutations cause 
the changes in tau protein splicing, phosphorylation state, and interactions with tubulin leading to 
prominent neurofibrillary tangles found in AD patients (Goedert, 2005). Tau mutations themselves 
do not cause AD, and their role in AD pathology is unclear. Current research shows that reducing 
tau pathology has been linked to improving cognitive impairment in learning and memory (Iqbal 
et al., 2010). Overall, these findings suggest that combining tau mutations with APP and PS1 
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mutations provide an aggressive mouse phenotype with a combination of AD pathologies that 
strongly mimic what is seen in human AD patients (Hall and Roberson, 2012). 
 The AD-like pathology of 3xTG-AD mice has been well described in previous studies. 
These mice express human APP within the pyramidal cell layer of the hippocampus as early as 
two months of age (Belfiore et al., 2019). The three transgenes cause 3xTG-AD mice to first 
develop extracellular Aβ deposition and tau pathology at six months of age  (Oddo et al., 2003; 
Belfiore et al., 2019). Neuroinflammation marked by microglia activation  in the hippocampus is 
also evident in these mice as early as six months and increases with age (Belfiore et al., 2019). 
Behaviour deficits have also been reported in 3xTG-AD mice at 6.5 months of age, as indicated 
by spatial and memory deficits in the Barnes maze (Stover et al., 2015). Morris water maze testing 
has shown differences in learning and memory in 6-month-old 3xTG mice compared to control 
B6129FS mice (Stimmell et al., 2019). These findings highlight the utility of the 3xTG mouse 
model due to the presentation of pathological and cognitive features reminiscent of human AD.  
 
1.10 Rationale 
  
Excess production of ROS, causing oxidative stress in the brain, is a core pathological 
feature of AD (Valko et al., 2007). The use of non-specific antioxidants treatments has led to 
inconsistent results due to physiological barriers common in human subjects and preclinical 
models of AD. These barriers include the degradation of therapeutics in the blood and the 
inability of candidate agents to cross the BBB to penetrate the brain (Moosmann and Behl, 
2002). Current research has indicated that the dysfunction of peroxisomes, a cellular organelle, 
contributes to this increase in harmful ROS (Cipolla and Lodhi, 2017). Peroxisomes play a 
crucial role in ROS homeostasis balancing the production of H2O2  from β-oxidation of fatty 
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acids with antioxidant functions of the enzyme catalase, which is active within the organelle 
(Bonekamp et al., 2009).  As the brain ages, progressive dysfunction of peroxisomes and 
decreased localization of catalase into the organelle contributes to elevated ROS contributing to 
the oxidative stress response in AD (Cheignon et al., 2018). This phenomenon has also been 
observed in preclinical rodent models of AD. In particular, the 3xTG AD mouse  used in the 
present study has elevated levels  of  PMP70, a peroxisomal population marker, as early as 3 
months of age reflecting the need for more efficient fatty acid β-oxidation. (Fanelli et al., 2013). 
Increased markers of lipid peroxidation and oxidative stress are also observed in 3xTG AD mice 
prior to traditional neuropathological hallmarks indicating the necessity for antioxidant therapy 
at the early stages of AD (Resende et al., 2008). The engineered CAT-SKL used in our lab can 
target this early AD pathology by effectively targeting peroxisomes and providing organelle-
based antioxidant, anti-inflammatory effects (Koepke et al., 2007; Giordano et al., 2014; Nell et 
al., 2017). 
A major obstacle with using CAT-SKL as a therapeutic is finding a method to efficiently 
and safely deliver the enzyme to the brain while minimizing off-target effects. We proposed that 
packaging CAT-SKL into exosomes could overcome this obstacle (Iraci et al., 2016). The use of 
exosomes is a promising delivery method as it can cross the BBB, thereby delivering therapeutics 
to cells of the CNS (Betzer et al., 2017; Li et al., 2017). Previous work by Haney et al. also 
demonstrated that exosomes loaded with endogenous catalase decreased neuroinflammation and 
increase neuronal survival in a mouse model of Parkinson’s disease (PD) (Haney et al., 2015). 
Early stages of PD and AD exhibit similar pathologies such as microglia activation, excessive 
secretion of ROS, and lower levels of antioxidant enzymes (Xie et al., 2014). Therefore, exosome-
mediated delivery of CAT-SKL is an intuitive strategy to target ROS in 3xTG AD mice. 
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1.11 Hypothesis and aims 
 
Overarching Thesis Hypothesis:  
Intranasal administration of exoCAT-SKL will penetrate the BBB and provide non-toxic, 
targeted antioxidant protection in mice. 
Aim 1:  
Demonstrate that intranasal administration of exoCAT-SKL can penetrate the BBB, assess the 
brain biodistribution, and determine potential toxicity in young healthy mice. 
Aim 2:  
Assess the protective effects of prophylactic intranasal administration of exoCAT-SKL using 
pathological, biochemical, and behavioural outcomes in control B6129FS and 3xTG AD mice. 
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Section 2: METHODS 
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2.1 Isolation of naïve exosomes and biotinylated catalase-SKL (bCAT-SKL) 
Naïve exosomes from Raw 264.7 macrophages were collected and isolated using gradient 
centrifugation and were provided by our collaborators Dr. Batrakova (UNC Eshelman School of 
Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA). The preparation 
and purification of bCAT-SKL and CAT-SKL was provided by the Shilton laboratory (Schulich 
School of Medicine and Dentistry, Western University, London, ON, CA). The methods used to 
isolate exosomes are previously described by Haney et al. (Haney et al., 2015). The genetic 
reengineering of the catalase enzyme and purification of bCAT-SKL or CAT-SKL is as previously 
described (Koepke et al., 2007).  
 
2.2 ExoCAT-SKL preparation 
A sonication technique was implemented to incorporate biotinylated CAT-SKL (bCAT-
SKL) into exosomes. Naïve exosomes isolated from Raw 264.7 macrophages were diluted in 
phosphate-buffered saline (PBS) to a concentration of 0.15 mg/mL exosome protein. A bCAT-
SKL solution of 0.5 mg/mL was prepared. 250 μL of exosomes solution was combined with 125 
μL of bCAT-SKL to achieve a final concentration of 0.1 mg/mL of total protein. This bCAT-SKL 
and exosome mixture was then sonicated for six cycles of 4 seconds pulse and 2 seconds pause 
(output power 9 watts – level 3), chilled on ice for 2 minutes, and sonicated again for six cycles of 
4 seconds pulse and 2 seconds pause (Sonic Dismembrator Model 100, Fisher Scientific). The 
sonicated mixture was then chilled on ice for 5 minutes, followed by a 37 °C water bath for 10 
minutes, and 30 minutes at room temperature. The bCAT-SKL loaded exosomes (exoCAT-SKL) 
were subsequently purified from unbound bCAT-SKL in solution by gel-filtration/size exclusion 
chromatography with Sepharose CL-6B column (Sigma-Aldrich) or the Optima MAX-XP 
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Benchtop Ultracentrifuge at 50 k RPM for 70 minutes using an MLA130 rotor at 4 oC. (Beckman 
Coulter, California, USA). A total of 24 fractions of 1 mL each were collected from the gel-
filtration chromatography column. For exoCAT-SKL purified using ultracentrifuge methods, the 
supernatant from the ultracentrifuge solution was replaced with 0.1 M phosphate buffer solution 
(PBS) and spun down again at 50 k RPM for 70 minutes at 4 oC. The remaining exoCAT-SKL 
pellet was resuspended in 0.2 M sucrose solution. ExoCAT-SKL purified by ultracentrifuge was 
stored at -80 oC for up to 5 weeks and underwent one freeze-thaw cycle before use. Gel-filtration 
and western blot techniques, as described above, were implemented to confirm successful 
ultracentrifuge purification and activity following one freeze-thaw cycle. A flowchart depicting 
the methods of exosome loading of catalase-SKL and purification of exoCAT-SKL is displayed in 
figure 1.  
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Figure 1. Flowchart depicting methods of exosome loading of CAT-SKL and purification. 
250 uL of exosome stock (0.15 mg/ml) is sonicated with 125 uL of 0.5mg/mL CAT-SKL. Two 
methods of purification of loaded exoCat-SKL from free CAT-SKL are implemented: 1) by gel 
Filtration and 2) by ultracentrifugation.  Loading of exosomes is verified via BCA and H2O2 
decomposition assays, and Western Blots (exosome markers: CD9, TSG101, HSP70). Dotted 
arrows represent one-time validation techniques by gel-filtration and western blots of collected 
supernatant and re-dissolved exoCAT-SKL from ultracentrifugation. Confirmed loading and 
purification of exoCat-SKL precede intranasal injection. 
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2.3 ExoCAT-SKL verification 
Following exoCAT-SKL loading and purification, western blot techniques were 
implemented to identify fractions containing exoCAT-SKL or CAT-SKL as well as verify 
ultracentrifuge methods. Protein concentrations of each fraction were determined using 
bicinchoninic acid assays (Thermo Fisher Scientific, Massachusetts, USA). Exosome membrane 
proteins, TSG101 and CD9, were detected using primary rabbit anti-TSG101 (1:1000; Abcam, 
Massachusetts, USA) or rabbit anti-CD9 (1:500; Abcam, Massachusetts, USA) antibodies 
respectively. Supplemental exosome protein markers, HSP70, were detected using anti-HSP70 
(1:1000; Abcam, Massachusetts, USA). CAT-SKL protein bands were detected using rabbit anti-
catalase (1:1000; Abcam, Massachusetts, USA) antibodies. Membranes were incubated using 
secondary horseradish peroxidase-conjugated goat anti-rabbit antibodies, and protein bands were 
detected using chemiluminescence substrate and visualized on a ChemiDoc Imaging System 
(BioRad, Philadelphia, USA). 
Catalase activity of prepared exoCAT-SKL was determined by hydrogen peroxide (H2O2) 
decomposition assays (Storrie and Madden, 1990; Koepke et al., 2008; Walton and Pizzitelli, 
2012). Protein concentrations of each fraction were determined using bicinchoninic acid assays 
(Thermo Fisher Scientific, Massachusetts, USA). Samples of each fraction collected from the gel-
filtration column were added to a reaction mixture of 0.02 M imidazole buffer (pH 7.0), 1 mg/mL 
bovine serum albumin (BSA), 0.2% Triton-X, and 0.06% hydrogen peroxide and incubated at 
room temperature for 10 minutes. The reaction was completed using a titanium oxysulfate stop 
solution (TiOSO4 in 2N H2SO4), which reacts with the remaining hydrogen peroxide not 
decomposed by the CAT-SKL to produce a yellow peroxotitanium complex. Optical density (OD) 
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of each sample was measured at 405 nm, and catalase activity was calculated based on the 
difference in OD per minute per mg total protein.  
 
2.4 Animal Handling and Care 
All animal handling and experimental procedures were approved by Western University 
Animal Care Committee (AUP 2018-068) and carried out in accordance with the guidelines of the 
Canadian Council on Animal Care and National Institute of Health Guides for the Care and Use 
of Laboratory Animals. For Aim 1, 29 wildtype (C57BL6) mice (17 males, 12 females) between 
the ages of eight and 16 weeks were involved in the study. For Aim 2, a total of 19 animals, nine 
3xTG-AD mice and ten control (B6129SF2/J), were used in the study. All mice were housed under 
standard conditions (12:12 light/dark cycle, at 22-24°C) and maintained on a standard diet 
provided ad libitum. 
 
2.5 Aim 1 – Timeline 
The timeline for aim 1 of the study is shown in figure 2.  
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Figure 2. Aim 1 timeline. Biotinylated CAT-SKL was loaded into exosomes via six cycles of 
sonication for 4 seconds and 2 seconds in-between. The loaded exosomes (exoCAT- SKL) were 
subsequently purified from unbound CAT-SKL using either gel filtration or ultracentrifugation. 
Loading of exosomes was verified via BCA and H2O2 decomposition assays and Western Blots 
(exosome markers: CD9, TSG101, HSP70).  Male and female 8-week old C56BL/6 wildtype mice 
received intranasal administrations of empty exosomes, low dose exoCAT- SKL (30 μL), or high 
dose exoCAT-SKL (60 μL), once per week for four consecutive weeks. Mice were subsequently 
sacrificed and processed for tissue collection. Pathological and histological assessments were 
performed on the brain as well as off-target tissue.  
 
2.6 Aim 1 – Treatment groups and dosing regimen  
Animal numbers for each experimental group were as follows: male empty exosomes, n= 
7; male low exoCAT-SKL, n=5; male high exoCAT-SKL, n= 5; female empty exosomes, n= 2; 
female low exoCAT-SKL, n=5; female high exoCAT-SKL, n=5. Mice assigned to high exoCAT-
SKL groups were subjected to 3 intranasal administrations of 10 μL per nostril of prepared 
exoCAT-SKL while mice assigned to low exoCAT-SKL groups were subjected to 3 sequential 
intranasal administration of 5 uL per nostril. All intranasal administrations were performed by 
holding mice in a supine position and held there for 2 minutes following each administration. Mice 
assigned to the empty exosome group were subjected to 3 intranasal administration of 5 uL of 
exosomes per nostril. All mice received intranasal administration of empty exosomes, low or high 
dose exoCAT-SKL once per week for four consecutive weeks. 
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The dosing regimen to test the safety of intranasal exoCAT-SKL injection in this study is 
based upon previous work by Nell et al. in which rats were treated with intraperitoneal CAT-SKL 
injections once per week for four sequential weeks at 1 mg/kg (Nell et al., 2017). A similar 
injection paradigm was explored by Giordano et al. in which C57Bl/6 mice were subcutaneously 
injected once a week with CAT-SKL for 3 to 4 months at 1 mg/kg (Giordano et al., 2015). In this 
study, multiple doses, in addition to empty exosomes, were used to determine any potential dose-
dependent responses. 
 
2.7 Aim 2 – Pilot study timeline 
The timeline for aim 2 of the study is shown in figure 3.  
 
Figure 3. Aim 2 pilot study overview. CAT-SKL was loaded into exosomes via six cycles of 
sonication for 4 seconds and 2 seconds in-between. Loaded exosomes were subsequently purified 
from unbound CAT-SKL using ultracentrifugation.  Loading of exosomes was verified via BCA 
and H2O2 decomposition assays and Western Blots (exosome marker: CD9).  Batches of CAT-
SKL loaded exosomes (exoCAT-SKL) were stored at -80oC for up to 5 weeks for subsequent 
injections.  Male and female 8-week old B6129SF2/J control mice, 3xTG-AD mice, received 
intranasal administrations of empty exosomes, or 60 uL of exoCAT-SKL once per week for 24 
consecutive weeks. Immediately following the last injection, the Morris water maze task was 
implemented to evaluate mouse behaviour, learning deficits, memory and cognitive impairments. 
Mice were sacrificed and perfused following behavioural testing; the brains and off-target tissue 
were collected and processed. Pathological and histological assessments were performed on all 
tissue.   
 
2.8 Aim 2 – Treatment groups and numbers 
The treatment groups and numbers for aim 2 of the study is shown in figure 4.  
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Figure 4. Aim 2 cohort 1 treatment groups and numbers. A total of 10 B6129SF2/J control 
mice and nine 3xTG-AD mice make up cohort 1 of Aim 2. Of the control mice, listed following 
are the treatment groups: males receiving empty exosomes, females receiving empty exosomes, 
males receiving high dose exoCAT-SKL, females receiving high dose exoCAT-SKL. Of the 3xTG 
mice, listed following are the treatment groups: males receiving empty exosomes, females 
receiving empty exosomes, males receiving high dose exoCAT-SKL, females receiving high dose 
exoCAT-SKL.  
 
 
2.9 Euthanasia and Tissue Collection 
Following the final injection (week 4), mice were euthanized using a CO2 chamber and 
weighed. Transcardial perfusion using 0.01 M PBS (pH 7.35), followed by 4% paraformaldehyde 
(pH 7.35), was performed for all mice. Brains were subsequently extracted, weighed, and 
submerged in paraformaldehyde for 24 hours and then transferred to a 30% sucrose solution until 
brains were saturated and fully submerged. Brains were sectioned coronally on a cryostat at 30 μm 
thickness approximately from bregma 3.75 mm to bregma -7.50 mm, sorted into series and stored 
in cryoprotectant at -20°C until used for histological and immunofluorescent techniques. All other 
organs were harvested, weighed, trimmed, and stored within cassettes and embedded in paraffin 
wax. As per the Society of Toxicologic Pathology, a list of all organs collected for histopathologic 
1 
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examinations is listed in Table 1 (Bregman et al., 2003).  
 
 
2.10 Histology  
Organs and brain sections were mounted onto slides and stained with 0.1% Mayer’s 
hematoxylin solution and 0.5% eosin Y solution, dehydrated, and coverslipped at the Robarts 
Research Institute Molecular Pathology Core Facility. Free-floating brain sections were pre-
washed in 0.01 M PBS, mounted on glass slides, and dried overnight.  
 
2.11 Immunofluorescence 
Immunofluorescence was performed on free-floating sections to visualize bCAT-SKL in 
the brain. Following PBS washes, sections were blocked in 1% BSA diluted in 0.01 M PBS/0.1% 
Triton X and subsequently incubated in Streptavidin Texas Red Conjugate (1:250, Abcam, 
Massachusetts, USA) for 2 hours diluted in antibody buffer. Sections were mounted on glass slides, 
Table 1: List of tissues included for histological examination 
Organ Systems Organs 
Secretory Glands 
 
Adrenal, Harderian, Kidney, Mammary, Parathyroid, 
Pituitary, Pancreas, Salivary, Thymus, Thyroid 
Muscular Skeletal 
 
Femur with articular cartilage, Bone marrow, Skeletal 
muscle (thigh), Skin 
Reproductive 
 
Epididymis, Seminal Vesicle, Testes, Ovary, Prostate, 
Uterus, Vagina 
Central and Peripheral Nervous 
 
Brain, Eye with optic nerve, Peripheral nerve (sciatic), 
Spinal cord (cervical, midthoracic, lumbar) 
Gastrointestinal Tract 
 
Cecum, Colon, Duodenum, Esophagus, Gall Bladder, 
Ileum, Jejunum, Liver, Stomach, and Urinary Bladder 
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and DAPI fluorescent mounting medium (Abcam, Massachusetts, USA) was applied, and slides 
were subsequently coverslipped.  
 
2.12 Immunohistochemistry 
Immunohistochemistry was performed on free-floating sections to visualize microglia in 
the brain. Following PBS washes, sections were blocked in 1% horse serum diluted in 0.01 M 
PBS/0.1% Triton X and subsequently incubated overnight at 4ºC in primary rabbit polyclonal 
antibody against the ionized calcium-binding adaptor molecule-1 (anti-Iba-1; 1:1000; Wako 
Chemicals USA Inc., Richmond, VA, USA). Sections were subsequently incubated with 
biotinylated anti-rabbit secondary antibody (1:500, Vector Laboratories, Inc. Burlingame, CA, 
USA) followed by a 1-hour incubation with avidin-biotin complex (ABC kit, Vector Laboratories, 
Inc. Burlingame, CA, USA) reagent. Sections were developed using 0.05% 3, 3’ diaminobenzidine 
tetrahydrochloride (Sigma-Aldrich, St. Louis MO, USA). Stained sections were then mounted on 
glass slides, air-dried, dehydrated in increasing concentrations of ethanol and xylene, and 
coverslipped with DePex mounting media (DePex, BDH Chemicals, Poole, UK).  
 
2.13 Microscopy 
Immunofluorescent, immunohistochemical, and histological imaging of organs and brain 
sections were taken using Nikon Eclipse Ni-E upright microscope with a Nikon DS Fi2 black and 
white camera head or colour camera. Images were taken using the NIS-Elements Imaging Software 
Version 4.30.02 (Nikon Instruments Inc., Melville, NY, USA) with consistent settings. Brain 
regions of interest included the prefrontal cortex, striatum, dorsal and ventral hippocampus, and 
the cerebellum. 
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2.14 Immunohistochemistry Quantification 
Entire brain sections stained for IBA1 positive cells were imaged at 2X to quantify changes 
in general microglia populations.  Sections of bregma 1.7 mm to bregma 1.8 mm were screened 
for positive IBA1 signal to determine regions of interest.  All analysis and quantification were 
carried out using 64-bit ImageJ software (Version 1.48u4, Wayne Rasband, National Institutes of 
Health, Bethesda, MD, USA). Areas of interest included the hippocampus and the corpus callosum 
and were manually outlined using the polygon selection tool. Selected areas were cropped and 
converted into grayscale 8-bit images and underwent universal thresholding. The percent area of 
positive IBA1 signal (percent of the total area) was measured for each region and expressed as a 
weighted mean.  
 
2.15 Behaviour: Morris Water Maze  
To assess brain areas associated with AD, cognitive testing using preclinical animal models 
has proven useful.  Hippocampal dependent spatial learning and memory can be assessed in 
rodents using the Morris water maze (MWM) task, first developed by Richard Morris in the early 
1980s (Morris, 1984). Tools such as the Morris water allows for the investigation of behavioural 
deficits caused by vulnerable brain areas as well as the impact of novel drugs. The MWM protocol 
published by Frame et al. 2019 was used in this study and explained as followed (Frame et al., 
2019).  
 
MWM equipment and layout:  
The objective of the task is for each mouse to learn the location of an escape platform in a 
circular polyurethane water tank, 122 cm in diameter, 81 cm height (San Diego Instruments, 
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catalogue number: 7000-0723, USA) using distal spatial cues. An escape platform made of clear 
acrylic, 10 cm diameter, 56 cm height (San Diego Instruments, catalogue number: 7500-0310, 
USA) was hidden in the pool using an opaque water mixture of non-toxic white tempera paint 
(0.34 g/L). The pool was filled within 20 cm to the top such that the escape platform was 
submerged ~1 cm below the surface. The water temperature was maintained at 24 ± 1°C 
throughout all testing days. Different spatial cues (distinct in colour and shape; blue triangle, 
yellow cross, red heart, green circle, grey diamond) were placed around the tank on the north, east, 
south and west walls of the testing area with transparent tape 1-2 m away from the pool. A camera 
was placed on the ceiling directly above the tank, allowing for complete capture of the entire tank 
in the same plane. Using ANY-Maze software (ANY-maze, Stoelting CO, USA), a virtual map of 
the MWM tank was drawn. The pool was virtually divided into four equal quadrants using 
horizontal and vertical lines that cut through the center point. Quadrants were labelled North-east, 
North-west, South-west, and South-east. The submerged exit platform area was also virtually 
marked using the ANY-maze software. All mice completed an 8-day protocol – 3 days of 
habituation, four days of learning, and a probe trial for 24 h long-term memory on the final day.   
 
Habituation period: 
All mice underwent three days of habituation. Mice were acclimatized to the holding area 
for 30 minutes on day 1 and returned to the normal housing room. On day 2, each mouse was 
placed on the exit platform positioned in the center of the maze. Immediately after placing the 
mouse on the platform, the mouse was given 15 uninterrupted seconds to acclimate to the exit 
platform and extra-maze visual cues. On day 3, mice were acclimatized to the training procedure. 
The exit platform remained in the center of the maze in the testing area. The trial began when a 
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mouse was placed in the water on the perimeter of the maze at a randomly chosen cardinal position 
(south) facing the wall of the pool. Each mouse was given 90 seconds to find the exit platform. 
Once the mouse found the platform, the mouse was again given 15 seconds before removing it 
from the testing area.  
 
Learning period: 
Over four days, four training sessions were implemented to induce spatial learning 
following the acclimation period. The exit platform was moved from the center of the pool to the 
center of the Northwest quadrant for the duration of all learning trials. The objective of these trials 
was to have the mice recognize the extra-maze visual cues to help establish the spatial location of 
the hidden exit platform. On the first day, each mouse performed 4 trials with a 10-minute inter-
trial time interval starting at the same cardinal position (south) used during the habituation session 
and facing the pool wall. Mice were given 90 seconds to search and locate the exit platform. An 
additional 15 seconds was given to the mouse to sit on the platform and absorb the surroundings. 
If the mouse had not found the platform in the allocated time, the mouse was gently guided to the 
platform and ensured 15 seconds on the platform before being removed from the pool. For each 
subsequent trial, mice were released in the cardinal direction that was one quarter turn clockwise 
(east, north, then west) from the previous trial. The initial starting position for each subsequent 
day was one quarter turn clockwise from the starting position of the previous day. Using the ANY-
maze software, each mouse's latency and distance to the exit platform, and mean swim speed was 
recorded. 
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Probe trial: 
A probe trial (exit platform was removed from the pool) was conducted to assess 24-hour 
long-term memory following the last learning trial. The probe trial began with each mouse being 
placed at the same cardinal direction (north) used during the habituation period. Mice were allowed 
60 seconds to explore the maze. As recorded using ANY-maze software, the amount of time spent, 
and the distance travelled in the target quadrant (Northwest - where the exit platform had been 
during the learning period) is taken as an index of the mouse's learning and 24-hour memory 
capacity. Mean swim speed and latency to where the exit platform had previously been was also 
analyzed. 
 
Flag Trial:  
Immediately following the probe trial, a flag trial was implemented to test the visuospatial 
navigation of each mouse. This test was used to control for potential differences in the MWM task 
between mice attributed to motivation or visual acuity. Extra-maze visual cues were removed from 
the testing area, and the exit platform was returned to the pool and placed in the center of the 
southeast quadrant diametrically opposite the original position (northwest) of the learning period. 
A flag was attached to the platform above the surface of the water, marking its location. Each 
mouse was allowed to acclimate to the new set of conditions and placed on the platform for 30 
seconds. Immediately after, each mouse was given a second trial and placed back in the pool at 
the same cardinal position (south) as the habituation period facing the wall. Due to the removal of 
extra-maze visual cues, the platform's location can only be discovered due to the flag's presence. 
The latency and distance travelled to the platform, as well as mean swim speed was recorded using 
ANY-maze software. 
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2.16 Data and Statistical Analysis  
Statistical analysis was performed using GraphPad Prism 6.0. Collected data were analyzed 
by either a three-way or two-way analysis of variance (ANOVA), followed by a Fisher’s LSD test 
where applicable. All data are expressed as the mean ± the standard error of the mean (SEM) with 
statistical significance considered at a p-value < 0.05. Statistical significance is indicated using 
symbols * and ‡.  
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Section 3: RESULTS 
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3.1 Aim 1 Results: 
 
3.1.1 bCAT-SKL loaded exosomes can be purified using gel filtration and maintain enzymatic 
activity. 
Short burst sonication was implemented to load bCAT-SKL into naïve exosomes derived 
from Raw 264.7 macrophages by disrupting the exosome membrane allowing for bCAT-SKL 
incorporation. Sonication was used due to its high loading efficacy compared to other protein 
incorporation techniques such as saponin permeabilization, freeze-thaw cycles, or extrusion 
(Haney et al., 2015). Unbound bCAT-SKL was removed using gel filtration chromatography with 
a Sepharose 6BCL column as described in the methods. Protein concentrations of collected 
fractions were measured using a BCA assay to confirm the separation of packaged and unpackaged 
bCAT-SKL (Figure 5A).  Results of the representative assay demonstrated that fractions 6 and 7 
contained relatively higher protein concentrations. The first peak (fractions 6 and 7) corresponds 
to both exosome proteins as well as packaged bCAT-SKL. The second protein peak (fractions 9-
14) corresponded to the unbound bCAT-SKL. This double peak pattern was mirrored in bCAT-
SKL enzymatic activity, as indicated in a representative H2O2 decomposition assay of collected 
fractions (Figure 5B). Early fractions 6 and 7 correspond to the catalase activity of exosome 
packaged bCAT-SKL, while later fractions 9-14 showcase the catalase activity of unbound bCAT-
SKL. Western blot techniques were used to confirm the presence of both exosome proteins and 
bCAT-SKL in early fractions and bCAT-SKL alone in later fractions (Figure 5C). Supplemental 
exosome markers CD9 and HSP70 were also utilized to confirm the presence of loaded exosomes 
(Figure 2D). The separation function of gel-filtration chromatography is dependent on molecular 
size. Larger molecules are filtered through the column at a faster rate than smaller molecules. 
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bCAT-SKL (a smaller molecule than exosomes) can only be collected into earlier fractions if 
incorporated into exosomes. The combination of all three techniques demonstrated the successful 
loading and purification of exoCAT-SKL without disrupting its enzymatic activity. 
 
 
 
Figure 5. Loaded exoCAT-SKL can be purified using gel-filtration chromatography.  
A) Representative BCA assay of collected fractions following gel filtration. The protein peak 
corresponding to exosome packaged bCAT-SKL occurred in early fractions (6-7; red) while the 
unbound catalase protein peak occurred in later fractions (10-14; blue). B) Representative H2O2 
decomposition assay of collected fractions following gel filtration. The H2O2 decomposition 
activity peak corresponding to exosome packaged bCAT-SKL occurred in early fractions (6-7; 
red) while the unbound catalase activity peak occurred in late fractions (9-16; blue). Fractions 9-
16 displayed catalase activity outside the linear range of the H2O2 decomposition assay.  C) 
Representative western blot confirmed the presence of catalase and exosomes in fraction 6. 
Unbound catalase was found in later fractions 11-14. D) Supplemental exosome markers CD9 (24 
kDa) and HSP70 (70 kDa) were used to confirm the presence of loaded exosomes in gel filtration 
fractions.  
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3.1.2 Ultracentrifuge purification of ExoCAT-SKL and stability of enzymatic activity following 
freeze-thaw cycle 
Ultracentrifuge purification was used as an alternative method to produce exoCAT-SKL. 
Stronger centrifugal forces were required to pellet CAT-SKL compared to exoCAT-SKL due to 
their difference in molecular weight. An MLA13-rotor spun at 50 k RPM, as used in this study, 
translated to 100,000 x g force and had been shown to pellet exosomes (Szatanek et al., 2015). 
Western blot techniques were implemented to confirm the successful purification of exoCAT-SKL 
using ultracentrifuge methods (Figure 6A). Exosome membrane protein, CD9, and CAT-SKL 
proteins were found within the resuspended pellet, and only CAT-SKL protein was found in the 
first supernatant. Trace levels of CAT-SKL protein were found in the second supernatant, 
confirming the successful removal of unbound CAT-SKL.  The catalytic activity of purified 
exoCAT-SKL before and after one freeze-thaw cycle was confirmed using H2O2 decomposition 
assays (Figure 6C). Thawed exoCAT-SKL was also filtered through a gel-filtration column, and 
western blot assays of collected fractions confirmed the presence of CAT-SKL within exosomes 
(Figure 6D).  Results of the western blot and H2O2 decomposition assays confirm successful 
exoCAT-SKL ultracentrifuge purification and retainment of enzymatic activity following one 
freeze-thaw cycle.  
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Figure 6. Loaded exoCAT-SKL can be purified using ultracentrifuge techniques, and thawed 
exoCAT-SKL retains enzymatic activity. A) Representative western blot confirmed the presence 
of both CAT-SKL and exosomes in the resuspended exoCAT-SKL pellet (labelled EXO CAT). 
Only CAT-SKL was found in the first supernatant and trace levels in the second supernatant. B) 
Representative H2O2 decomposition assay showcased strong exoCAT-SKL enzymatic activity 
before freezing. A 1:50 dilution of the resuspended exoCAT-SKL equated to 9 ng/µL CAT-SKL 
C) Representative western blot confirmed the presence of CAT-SKL and exosomes in early 
fractions (fractions 5-7) collected from gel-filtration assay following one freeze-thaw cycle. D) 
Representative H2O2 decomposition assay showcased thawed exoCAT-SKL retained strong 
enzymatic activity.  
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3.1.3 Intranasal administration of exoCAT-SKL demonstrates the ability to penetrate the BBB in 
vivo. 
Immunofluorescent and confocal imaging techniques were implemented to visualize 
bCAT-SKL deposition in WT mice brains. Mice were intranasally administered empty exosomes, 
low, or high doses of exoCAT-SKL (Figure 7). bCAT-SKL was immunofluorescently labelled to 
identify its biodistribution 1 hour following the final administration. The imaging revealed diffuse 
bCAT-SKL positive signal throughout the brain (bregma 0.5 to bregma -2.75) including areas of 
interest such as the prefrontal cortex, corpus callosum, and the hippocampus. Higher magnification 
of brain sections showed bCAT-SKL localization in the perinuclear region (Figure 7 - yellow 
arrow) and the vessel walls (Figure 7 - white arrow). Images of the control brain injected with 
empty exosomes demonstrated a complete absence of bCAT-SKL fluorescent signal (Figure 7 - 
Control 40X). Fluorescent imaging of bCAT-SKL demonstrated that intranasal administration of 
exoCAT-SKL is an effective delivery mechanism to penetrate the BBB and target the CNS of 
mice.  
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Figure 7. Intranasal administration of exoCAT-SKL penetrated BBB in vivo. Pervasive 
biodistribution of biotinylated CAT-SKL (red) following low and high dose intranasal exoCAT-
SKL injection was observed throughout the brain. 40X magnification and 40X-Digital 
Enhancement (DE; 40X area resize) of the prefrontal cortex, corpus callosum and hippocampus 
are showcased. The white arrow in the figure showcases the vasculature deposition of bCAT-SKL. 
Yellow arrow showcases cellular deposition of bCAT-SKL.  
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3.1.4 Short-term in vivo exoCAT-SKL administration does not exhibit toxicity in the brain  
Histopathological analysis of H&E stained brain tissue determined whether degenerative 
or toxic changes occurred in mice following four weeks of exoCAT-SKL treatment compared to 
control mice (Figure 8). Serial sections throughout the brain (bregma 2.8 mm to bregma -6.6 mm), 
including anatomical structures encompassing predicted exoCAT-SKL absorption pathways such 
as the piriform cortex, were analyzed to account for widespread bCAT-SKL biodistribution. 
Representative images of the prefrontal cortex, corpus callosum, hippocampus, and cerebellum are 
showcased. Neuronal injury within the grey matter was not observed under microscopic 
examination in any of the treatment groups evidenced by the absence of eosinophilia of the 
cytoplasm, shrinkage or disappearance of the nucleolus, disintegration of the cell, amongst other 
characteristics of injury. Neuronal atrophy or neuronal necrosis was not observed in any treatment 
group. Reactive inflammation was not observed, and a normal distribution of neural cells was 
observed in all treatment groups. No vasculature abnormalities nor lesions were identified 
throughout the tissue and white matter tracks did not contain degenerative changes (i.e. 
vacuolation, spheroids). No evidence of toxicity was identified throughout the brain for all 
treatments and doses.   
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Figure 8. ExoCat-SKL does not cause toxicity in the brain in vivo. The prefrontal cortex 
(bregma 2.8 mm), corpus callosum (bregma 0.5 mm), hippocampus (bregma -1.8 mm), and 
cerebellum (bregma -6.6 mm) sections were selected to represent the entirety of the brain. All 
sections were examined for features of toxicity, including but not limited to spongiosis, neuron 
degeneration, inflammation, and vasculature abnormalities. Representative 10X magnification of 
boxed areas is showcased. All features of toxicity are negative in all areas of mice treated at 
different doses of exoCAT-SKL. 
 
 
 
 
 
100 µm 
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3.1.5 Short term in vivo intranasal exoCAT-SKL administration does not exhibit off-target toxicity. 
In addition to assessing the toxicity of exoCAT-SKL in the brain, off-target toxicity was 
assessed to validate the utility of this therapeutic approach. The Society for Toxicologic 
Pathology's (STP) best practices guideline for toxicologic histopathology was utilized to ensure 
high-quality histologic assessments. No significant differences were observed in relative organ 
weight of the brain, liver, spleen, nor in the thymus, heart, kidney, adrenal glands, testis and ovaries 
compared between treatment groups. All features of toxicity were negative in off-target  
tissue (Table 2). 
 
 
 
 
 
 
 
Table 2: Features of toxicity of tissues included for histological examination 
Organ Systems Organs Toxicity 
Secretory Glands 
 
Adrenal, Harderian, Kidney, Mammary, Parathyroid, 
Pituitary, Pancreas, Salivary, Thymus, Thyroid 
Negative 
Muscular Skeletal 
 
Femur with articular cartilage, Bone marrow, Skeletal 
muscle (thigh), Skin 
Negative 
Reproductive 
 
Epididymis, Seminal Vesicle, Testes, Ovary, Prostate, 
Uterus, Vagina 
Negative 
Central and 
Peripheral Nervous 
 
Eye with optic nerve, Peripheral nerve (sciatic), Spinal 
cord (cervical, midthoracic, lumbar) 
Negative 
Digestive 
 
Cecum, Colon, Duodenum, Esophagus, Gall Bladder, 
Ileum, Jejunum, Liver, Stomach, and Urinary Bladder 
Negative 
 
 
 47 
3.2 Aim 2 pilot study results 
 
3.2.1 Behaviour testing: Morris water maze 
The Morris water maze task was implemented to examine if 24 weeks of intranasal 
exoCAT-SKL injections improved memory or learning deficits in control and 3xTG AD mice. All 
mice underwent four days of learning, followed by a probe trial on the 5th day to assess 24-hour 
long-term memory. The amount of time spent, and the distance travelled in the target quadrant 
(area of the maze where the exit platform had been during the learning period) during the probe 
trial was taken as an index of each mouse’s learning and 24-hour memory capacity. 
 
Latency to platform and swim speed during the learning period 
Following the last exoCAT-SKL injection, all mice were subjected to a 4-day training 
regimen with four trials each day for a total of 16 spatial learning trials. No significant interactions 
between time, genotype, and treatment were observed for both latency to platform by trial and by 
day. A significant time-dependent effect was observed for the latency to platform by trial (F15,240 
= 4.154, P < 0.001) (Figure 9A), and for the latency to platform by day (F3,60 = 5.816, P < 0.01) 
(Figure 9B). No significant interactions between variables were observed in measured swim 
speeds. Significant genotype dependent differences in swim speed were observed between groups 
(Figure 9C). The control empty exosome group swam significantly slower than the 3xTG AD 
empty group across the days. 
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Figure 9. Morris water maze learning trials following 24 weeks of intranasal injections of 
either empty exosomes or high dose exoCAT-SKL. A) The mean latency to the exit platform 
for each treatment group per trial is plotted. Vertical dotted lines indicate the first trial of the 
following day (i.e. trial 5 is 24 hours following trial 4). Mice that did not reach the platform during 
the trial were recorded as 90 seconds (time indicating the trial endpoint). No significant 
interactions between time, genotype, and treatment were observed for the latency to platform by 
trial. A significant time-dependent effect was observed (F15,240 = 4.154, P < 0.001). B) The mean 
latency to the exit platform area of each treatment group per day is plotted. No significant 
interactions between time, genotype, and treatment were observed for the latency to platform by 
day. A significant time-dependent effect was observed (F3,60 = 5.816, P < 0.01). C) The mean swim 
speeds of each treatment group were compared per day during the learning trials. No significant 
interactions between variables were observed in measured swim speeds. Significant genotype 
dependent differences in swim speed were observed between groups The Control Empty group 
swam slower than both 3xTG groups on day 1, day 2, and day 3.  Significant differences were 
observed between Control High Dose ExoCAT-SKL group compared to both 3xTG groups on day 
3 and day 4. Values are presented as mean ± SEM (Three - way ANOVA).   
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Distance to the exit platform during the learning period 
The distance to the exit platform during the learning period accounts was analyzed to 
account for variability in swim speeds between treatment groups. No significant interactions 
between time, genotype, and treatment were observed for both distance to platform by trial and by 
day. Significant time-dependent (F15,240 = 3.340, P < 0.0001), genotype-dependent (F1,240 = 23.81, 
P < 0.0001), and treatment-dependent sources of variation (F1,240 = 5.503, P < 0.05) were observed 
in the distance to platform by trial (Figure 10A). In addition, significant time-dependent (F3,60 = 
5.639, P < 0.01), genotype-dependent (F1,60 = 19.85, P < 0.0001), and treatment-dependent sources 
of variation (F1,60 = 4.589, P < 0.05) were observed in the distance to platform by day. The same 
pattern was seen in the latency to the exit platform during the learning period.  
 
 
 
 
 
 
 
 
 
 
 
 
 
A) 
B 
1 9 13Day 2
0
5
10
15
20
25
Trials
D
is
ta
nc
e 
to
 p
la
tf
or
m
/tr
ia
l e
nd
po
in
t (
m
)
Control Empty
Control High Dose ExoCAT-SKL
3xTG Empty
3xTG High Dose ExoCAT-SKL
       5 
1 2 3 4
0
20
40
60
80
Days
La
te
nc
y 
to
 p
la
tf
or
m
/tr
ia
l e
nd
po
in
t (
s)
Control Empty
*Control High Dose 
ExoCAT-SKL
3xTG Empty
3xTG High Dose ExoCAT-SKL
 
 
 51 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Morris water maze learning trials following 24 weeks of intranasal injections of 
either empty exosomes or high dose exoCAT-SKL. A) The mean distance to the exit platform 
area of each group per trial is plotted. The distance to the platform reflects path efficiency. Vertical 
dotted lines indicate the first trial of the following day (i.e. trial 5 is 24 hours following trial 4). 
Mice that did not reach the platform during the trial were recorded with the total distance swam 
reflecting the trial endpoint. No significant interactions between time, genotype, and treatment 
were observed for the distance to platform by trial. Significant time-dependent (F15,240 = 3.340, P 
< 0.0001), genotype-dependent (F1,240 = 23.81, P < 0.0001), and treatment-dependent sources of 
variation (F1,240 = 5.503, P < 0.05) were observed in the distance to platform by trial. The distance 
to the platform was significantly shorter over the course of the trials for all treatment groups except 
for 3xTG AD mice treated with high dose exoCAT-SKL. B) The mean distance to the platform of 
each group per day is plotted. No significant interactions between time, genotype, and treatment 
were observed for the distance to platform by day. Significant time-dependent (F3,60 = 5.639, P < 
0.01), genotype-dependent (F1,60 = 19.85, P < 0.0001), and treatment-dependent sources of 
variation (F1,60 = 4.589, P < 0.05) were observed. Values are presented as mean ± SEM (Three - 
way ANOVA). 
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Probe trial: 24-hour long-term memory retention does not demonstrate significant differences 
Twenty-four hours following the last learning trial, mice were subjected to a probe trial. 
Several measurements were recorded as an index of each mouse's memory capacity: the percentage 
of time spent in the target quadrant (Figure 12A), the number of removed platform area entries 
(Figure 12 B), latency to removed platform area (Figure 12C) and distance to removed platform 
area (Figure 12D). No significant differences were observed in any of the interactions and 
measurements between all treatment groups. 
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Figure 11. Indications of short-term memory during the probe trial. A) The time spent in the 
target quadrant is expressed as a percent of the total time of the probe trial. The horizontal dotted 
line represents the theoretical amount of time spent in the target quadrant due to chance. No 
significant differences amongst groups were observed. B) The number of removed platform area 
entries per group are indicated. No significant differences were observed. C) The mean latency to 
the removed platform area of each group is plotted. Mice that did not reach the area during the trial 
were recorded as 60 seconds (time indicating the trial endpoint). No significant differences were 
observed. D) The mean distance to the removed platform area of each group is plotted. Mice that 
did not reach the area during the trial were recorded with their total swim distance during the entire 
trial. No significant differences were observed. Values are presented as mean ± SEM (Two–way 
ANOVA).  
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Flag Trial:  
On the final day immediately following the probe trial, a single flag trial was conducted as 
a control procedure to examine if any differences observed in the MWM task was attributed to 
extraneous factors such as visual impairment and lack of motivation. All mice were acclimated to 
a flag placed upon the platform indicating its position in the MWM. The latency to the flagged 
platform was recorded (Figure 12). No significant differences between genotypes, treatments, and 
interactions were observed demonstrating that all mice had similar motivation and abilities to find 
the exit platform.  
 
 
 
 
Figure 12. Latency to the platform during flag trial. The mean latency to the platform of each 
group is plotted. All mice reached the platform within the allocated trial time. No significant 
differences were observed between groups. Values are presented as mean ± SEM (Two – way 
ANOVA).  
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3.2.2 Anatomical changes 
 
Mice were weighed once a week on the day of the exoCAT-SKL intranasal administration 
for 24 weeks. The change in body weight was calculated as the mouse's weight on the day of 
sacrifice (Figure 13A) subtracted by the weight of the mouse on the first intranasal injection. No 
significant sources of variation were observed in the interactions between genotype and treatment 
for all measurements. No significant body weight changes were identified between all treatment 
groups (Figure 13C). Post-mortem brain weights were also recorded on the day of sacrifice (Figure 
13B). The relative brain to body weight was calculated as the ratio of the brain weight to the mouse. 
No significant differences were observed in normalized brain weights amongst all treatment 
groups (Figure 13D). 
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Figure 13. Weight gain, brain weight, and relative brain weight. A) The mean weight of each 
treatment group at time of sacrifice. B) Means of raw brain weight at the time of sacrifice of each 
treatment group is plotted. C) The mean change in body weight over 24 weeks of injections was 
tracked for all treatment groups. No significant differences were observed. D) The relative brain 
to body weight is expressed as a percentage of total body weight. No significant differences were 
observed between all treatment groups. Values are presented as mean ± SEM (Two - way ANOVA). 
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3.2.3 Long-term exoCAT-SKL administration does not exhibit toxicity in the brain in vivo. 
 
Histopathological analysis of H&E stained brain tissue determined whether degenerative 
or toxic changes occurred in mice that underwent 24 weeks of intranasal exoCAT-SKL treatment. 
Mimicking Aim 1, serial sections throughout the brain, were analyzed to account for widespread 
bCAT-SKL biodistribution. Representative images of bregma 2.5 mm to bregma -6.2 mm are 
shown (Figure 14).  
Neuronal injury within the piriform cortex, cerebral cortex, anterior and posterior corpus 
callosum, dorsal and ventral hippocampus, and the cerebellum was not observed under 
microscopic examination in any of the treatment groups. Features of toxicity examined included 
the absence of eosinophilia of the cytoplasm, shrinkage or disappearance of the nucleolus, 
disintegration of the cell, amongst other characteristics of injury. In addition, neuronal atrophy or 
neuronal necrosis was not observed in any treatment group. Reactive inflammation could not be 
accurately reported using H&E analysis; however, a normal distribution of neural cells was 
observed in all treatment groups. No vasculature abnormalities nor lesions were identified 
throughout the tissue and white matter tracks did not contain degenerative changes (i.e. 
vacuolation, spheroids). No evidence of toxicity was identified throughout the brain for both 
genotypes and treatments.  
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Figure 14. Chronic exoCAT-SKL injections do not cause toxicity in the mouse brain in vivo. 
Representative sections of bregma 2.5 mm to bregma -6.2mm are selected to portray the entirety 
of the brain. All sections are stained with hematoxylin and eosin for features of toxicity, including 
but not limited to spongiosis, neuron degeneration, inflammation, and vasculature abnormalities. 
Representative 10X magnification of boxed areas of all treatment groups is showcased. All 
features of toxicity are negative in all areas for control and 3xTG AD mice treated with empty 
exosomes and high doses of exoCAT-SKL. 
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3.2.4 Neuroinflammation: Microglia reactivity  
 
Immunohistochemical analysis of IBA1 stained brain tissue of mice intranasally injected 
with exoCAT-SKL for 24 weeks was performed to investigate microgliosis. Pathology in the 
corpus callosum and hippocampus were of particular interest due to their association with memory 
and cognitive function. Representative images of the of bregma 1.7 mm to bregma -1.8 mm are 
shown (Figure 15A). No significant differences were observed in the interactions between 
genotype and treatment. A significant genotype-dependent increase in Iba-1 positive microglia in 
the hippocampus (F1,32 = 34.57, P < 0.0001) and the corpus callosum (F1,15 = 8.984, P < 0.01) was 
observed. Both 3xTG AD groups had significantly more percent IBA1 microglia coverage in the 
hippocampus and corpus callosum than their control counterparts (Figure 15B,C).  
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Figure 15. Total microglia in the brain. A) Representative images of Iba-1 immunolabelled 
microglial cells throughout brain sections of bregma 1.7 mm to bregma 1.8 mm are showcased. 
2X digitally enhanced magnification of boxed areas of the left column is shown for all treatment 
groups. 2x digitally enhanced insets of areas of interest included the piriform cortex, corpus 
callosum, medial septal nucleus, and hippocampus. B) Percent area of IBA1 positive microglia in 
the hippocampus is shown. No significant differences were observed in the interactions between 
genotype and treatment. A significant genotype effect was observed (F1,32 = 34.57, P < 0.0001). C) 
Percent area of IBA1 positive microglia in the corpus callosum is shown. No significant 
differences were observed in the interactions between genotype and treatment. A significant 
genotype dependent effect was observed (F1,15 = 8.984, P < 0.01). Values are presented as mean ± 
SEM (Two - way ANOVA). 
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Section 4: DISCUSSION 
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The results of this study provided the foundation for using macrophage-derived exosomes 
to deliver the recombinant antioxidant, CAT-SKL, to the brain. This approach could act as a 
potential therapeutic strategy for many neurodegenerative disorders by addressing two 
complementary issues: i) an important antioxidant cargo, and ii) a therapeutically promising 
delivery method.  
The function of CAT-SKL in metabolizing H2O2 into less toxic derivatives and its ability 
to target peroxisomes directly holds tremendous promise for managing cellular ROS. CAT-SKL 
was previously shown to protect neurons, reduce cell death and neuroinflammatory responses 
elicited in cell culture models of neurodegeneration (Giordano et al., 2014). In addition, studies 
have shown intraperitoneal injections of CAT–SKL reduced neuroinflammation and memory 
deficits in a rat model of AD (Nell et al., 2017). Although CAT-SKL had been demonstrated to be 
protective in numerous preclinical models, these previous studies were limited by biodistribution, 
systemic degradation, and, most importantly, the inability to penetrate the BBB.  
 
4.1 Exosomes as therapeutic drug carriers 
Results from the current study (Figure 1 and Figure 2) demonstrated that sonication 
techniques could be used to incorporate CAT-SKL into exosomes successfully. The hydrophilic 
core of exosomes is a suitable environment for water-soluble compounds such as CAT-SKL (Jiang 
and Gao, 2017). This approach allowed CAT-SKL to be protected from degradation in vivo while 
maintaining H2O2 decomposition abilities (Figure 1 and Figure 2). Similar sonication techniques 
have been implemented to load exosomes successfully in other studies. Kim et al. reported that 
exosomes sonicated with chemotherapy medication, paclitaxel, did not disrupt the structure and 
content of exosome membranes and maintained stability in aqueous solution for over one month 
(Kim et al., 2016). In addition, Haney et al. also demonstrated mild sonication of exosomes in the 
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presence of endogenous catalase, provided effective loading capacity and improved its enzymatic 
stability against protease degradation (Haney et al., 2015).  
Gel-filtration and ultracentrifuge techniques, as used in this study, demonstrated successful 
purification of exoCAT-SKL, providing promise for standardized production and purification of 
loaded exosomes (Figure 1 and Figure 2A). ExoCAT-SKL enzymatic activity was not disrupted 
following a freeze-thaw cycle as measured by H2O2 decomposition assays (Figure 2D), allowing 
for long term storage in future studies. This work provides further evidence that exosomes could 
be a valuable tool as carriers of therapeutic proteins.  
 
4.2 Safety of exoCAT-SKL within the brain 
Although exoCAT-SKL holds tremendous potential as both an effective therapeutic and 
efficient drug transport technique, the safety of its use required investigation. The use of 
homologous exosomes in our study was derived from same-species monocytes, resulting in 
minimal immune responses (Ha, Yang and Nadithe, 2016). Thus, an emphasis was put on the 
toxicology profile of CAT-SKL in the brain and systemically in vivo. Accurate interpretation of 
mouse histology provided a fundamental step in determining the feasibility of exoCAT-SKL. 
Drug delivery through the intranasal route has been demonstrated as an effective and non-
invasive method for targeting drug uptake into the brain (Crowe et al., 2018b). This study 
demonstrated that the intranasal injection of exoCAT-SKL could successfully cross the BBB and 
deposit CAT-SKL into the brain (Figure 7). No apparent abnormalities nor features of toxicity 
were observed in the brains of mice treated for 4 weeks or 24 weeks of exoCAT-SKL injections 
in all treatment groups. This finding provided further evidence that CAT-SKL has non-toxic 
neuroprotective roles similarly described in other in vitro and in vivo studies (Giordano et al., 
2015; Nell et al., 2017). Standard catalase without the recombinant c-terminus loaded within 
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exosomes have also been shown to be neuroprotective in preclinical models of Parkinson's disease 
(Haney et al., 2015). The protective capacity of standard catalase in neurodegenerative models 
highlights the increased potential of CAT-SKL in similar preclinical experiments. 
 
4.3 Microgliosis 
Research in AD has established that neuroinflammation contributes to the pathogenesis of 
AD in addition to other hallmarks such as Aβ and neurofibrillary tangles (Raj et al., 2017). It is 
well established that microglia contribute to the inflammatory response through their interactions 
with Aβ and their frustrated phenotype, causing the release of pro-inflammatory cytokines, 
chemokines and ROS (Xiang et al., 2006; Hemonnot et al., 2019). The IBA1 marker of microglia 
was used to measure microgliosis with increased microglia reflective of neuroinflammation and 
microglia activation (Imai et al., 1996; Lee et al., 2017). Results from this study demonstrated an 
increased microglia response in 34-week-old 3xTG AD mice compared to their control counterpart 
independent of exoCAT-SKL treatment. Consistent with these findings, previous work by Belfiore 
et al. found elevated levels of IBA1 labelled microglia in the medial, caudal, and rostral 
hippocampus of 3xTG AD mice at 6 months of age consistent with these findings (Belfiore et al., 
2019). The current study found no significant differences in IBA1 labelled microglia in the corpus 
callosum or hippocampus between mice treated with exoCAT-SKL and mice treated with naive 
exosomes of either genotype (Figure 15). These findings contradict findings by Haney et al. which 
demonstrated that catalase reduced microgliosis in mice stereotaxically injected with 6-
hydroxydopamine, a neurotoxic compound used to destroy dopaminergic neurons (Haney et al., 
2015). In addition, Nell et al. 's findings demonstrated that intraperitoneal injections of CAT-SKL 
reduced microgliosis in the medial septal nucleus and thalamus of 6-month-old rats administered 
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with Aβ peptides (Nell et al., 2017). These contradictory results could be attributed to the 
concentration and frequency of exoCAT-SKL injections as well as the limited numbers used in 
this study. Nell et al. implemented intraperitoneal injections of CAT-SKL at 1 mg/kg once per 
week while Haney et al. implemented 10 intranasal injections every other day (Haney et al., 2015; 
Nell et al., 2017). The concentration of CAT-SKL that reached the brain was not quantifiable in 
this study, and preliminary results did not indicate CAT-SKL elicited a detectable effect on 
microgliosis  
  
4.4 Morris water maze 
The Morris water maze task was implemented to discern any learning and memory 
differences induced by genotype differences or 24 weeks of exoCAT-SKL injections (Morris, 
1984; Bromley-Brits, Deng and Song, 2011; Frame et al., 2019). Results from the MWM testing 
were preliminary, and discrepancies between our findings to that of others can be attributed to the 
lack of statistical power in Aim 2 of our study. All of the treatment groups demonstrated successful 
learning of the task by swimming to the platform significantly quicker and using less distance over 
the course of all trials except for the 3xTG High Dose exoCAT-SKL group (Figure 9, Figure 10). 
Genotype induced differences were not observed as the 3xTG Empty group performed similarly 
to Control Empty mice. This contradicts findings by Belfiore et al. that showcased 6-month-old 
3xTG-AD mice developed learning deficits compared to age-matched controls (Belfiore et al., 
2019). ExoCAT-SKL treatment showed behavioural benefits exclusively in control mice as the 
Control High Dose exoCAT-SKL group performed better during the learning period in both 
latency and distance travelled compared to the Control Empty group (Figure 9, Figure 10). Similar 
exoCAT-SKL induced improvements were not demonstrated in 3xTG mice and could be attributed 
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to the aggressive phenotype of the 3xTG-AD mice at the age of testing (8.5 months) (Stimmell et 
al., no date; Oddo et al., 2003; Sterniczuk et al., 2010). Increased statistical power could also 
discern potential differences amongst treatment groups during the probe trial.  
The flag trial acted as an important control to ensure that all the mice possessed the basic 
abilities to perform the tasks (Vorhees and Williams, 2006; Frame et al., 2019). These abilities 
include intact visual acuity, swimming away from the edge of the pool, and climbing onto the exit 
platform. The flag trial results did not identify any significant differences between the latency to 
the flagged platform among the treatment groups (Figure 12). This indicated that all of the mice 
had similar abilities to learn using visuospatial ques, swimming abilities, and motivation to find 
the platform. Therefore, any differences in learning and memory retention could be attributed to 
differences in genotype or treatment (Frame et al., 2019). 
  
4.5 Off-Target exoCAT-SKL toxicology 
Due to the inherent mechanisms of intranasal exoCAT-SKL delivery, off-target tissues 
were assessed to ensure the safety of repeated dosing. As with any intranasal drug, ExoCAT-SKL 
is likely to be aspirated and deposited into the lung, swallowed into the GI system, and distributed 
into the circulatory system (Erdő et al., 2018). Standard investigation of the relative organ weight 
of all tissues, including the brain, showed no significant differences in treatment groups and 
indicated no chemically induced changes to organs (data not shown). Histopathological assessment 
of the highlighted organs (as described in the methods) not only provides evidence that the 
intranasal administration of exoCAT-SKL is safe but also sheds light on the therapeutic potential 
of exoCAT-SKL for other organ disorders.  Although exoCAT-SKL has a high likelihood of 
depositing into the lung (Imai et al., 2015), the histopathological assessment of lung tissue 
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indicated no perceived abnormalities across all treatments exemplifying the safety of exoCAT-
SKL in terms of preserving the architecture and cellular makeup. In the liver, the absence of 
exoCAT-SKL toxicity supports other studies of subcutaneous injections of CAT-SKL being 
protective in preclinical models of diabetic retinopathy (Giordano et al., 2015). Assessments of 
the spleen across all treatments indicated that mice could tolerate exoCAT-SKL for all treatment 
dosages and durations. The absence of histopathological toxicity features in both the small and 
large intestines aligns with studies demonstrating protective effects of exogenous catalase in 
models of inflammatory bowel disease where exogenous catalase had been shown to decrease 
leukocytic ROS production, mucosal damage, and hyperemia (Ruh et al., 2000). Although the 
protective effects of exoCAT-SKL on off-target tissue were not investigated in the current study, 
the increased peroxisomal specificity of exoCAT-SKL may contribute to its safety. Compared to 
exogenous catalase, exoCAT-SKL limits the alterations of necessary redox biology residing in the 
cytoplasm or other organelles that maintain physiological functions (Valko et al., 2007; Finkel, 
2011; Schieber and Chandel, 2014). 
 
4.6 Limitations and future direction 
Two of the biggest limitations of this study are the lack of statistical power for Aim 2 and 
the use of mouse models to model human AD. Although it is common practice to use transgenic 
mice for preclinical research, the genetic and physiological differences between mice and humans 
cause transformative and translational discrepancies in clinical studies (Ellenbroek and Youn, 
2016). In addition, the statistical power of Aim 2 of this study was not adequate for evaluating the 
effects of exoCAT-SKL on behavioural and histological outcomes.  
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This study identified the distribution and safety of intranasal exoCAT-SKL administration; 
however, several questions remain regarding the efficacy and mechanisms of CAT-SKL. In 
particular, further investigation is required to identify the most effective dosing to prevent AD 
pathology in transgenic mice. Indicators of oxidative stress, such as the by-products of lipid 
peroxidation in brains of mice treated with and without exoCAT-SKL can be investigated using 
MALDI mass spectrometry (Leopold et al., 2018). In vitro experiments can also explore whether 
exoCAT-SKL is preferentially internalized within neural cell populations and the extent to which 
exoCAT-SKL can reduce ROS and oxidative stress in cell culture models. Future investigation 
can also assess the potential of exoCAT-SKL in ameliorating and even reversing AD outcomes in 
transgenic mice. The typical diagnosis of AD for most patients occurs following cognitive 
impairment and significant pathological load (Petersen, 2009).  Giordano et al. have demonstrated 
that CAT-SKL can reverse the neurite loss caused by Aβ peptide administration in vitro (Giordano 
et al., 2014). Assessing the potential of exoCAT-SKL to reduce and reverse pre-existing 
pathological and behavioural correlates will increase its practicality. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 71 
 
 
 
 
 
 
 
 
 
 
 
Section 5: CONCLUSION 
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Developing potential therapeutic drugs for nervous system disorders such as AD must 
consider the disease's complex and debatable pathophysiology. This study has developed methods 
to test the safety, biodistribution, and therapeutic potential of a new drug and delivery mechanism, 
exoCAT-SKL. Results from the current investigation have provided further evidence that 
exosomes can act as carriers of recombinant proteins as well as other potential therapeutic proteins. 
The innate ability of exosomes to penetrate the BBB increases its potential in treating 
neurodegenerative diseases. Furthermore, the peroxisome targeting ability of CAT-SKL allows for 
Control of ROS and oxidative stress at the site of production. 
CAT-SKL is a powerful antioxidant; however, its safety in the brain had never been 
investigated until now. A critical part of the risk assessment associated with exoCAT-SKL was 
assessing its toxicologic effects. Histopathology used in this study did not distinguish exoCAT-
SKL induced abnormalities from normal histological variations. Analysis of brain tissue 
determined no features of toxicity such as necrosis, fibrosis, inflammation, and growth 
disturbances (i.e. neoplasia, hyperplasia). Off-target toxicity analysis also did not present risks 
associated with short-term and long-term intranasal administration of exoCAT-SKL. 
AD is strongly tied to oxidative stress, lipid peroxidation, increased inflammatory 
mediators, and reduced antioxidant defences (Butterfield et al., 2001; Lull and Block, 2010; Cline 
et al., 2018). Although exoCAT-SKL did not demonstrate toxicity in mice, the efficacy of 
exoCAT-SKL in preventing AD pathology requires further analysis. Additional investigation is 
required to discern whether chronic exoCAT-SKL can reduce ROS and mediate 
neuroinflammation responses. Preliminary MWM maze results did not show behavioural 
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improvements in exoCAT-SKL treated 3xTD AD mice, but the promise remains in promoting 
learning and memory retention in wildtype mice. 
This study addressed several barriers of using protein biologics in a therapeutic setting by 
answering questions surrounding bioavailability, toxicity, and penetrating the BBB. The use of 
exosomes to deliver compounds to cells in need allows for the re-evaluation of other proteinaceous 
reagents. In future clinical studies, using a patient's own monocytes as a source of homologous 
exosomes could also allow this delivery method to bypass any immune responses. Thus, in an era 
of personalized medicine, the use of exosomes will constitute a personalized delivery method that 
holds tremendous promise. 
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AUP Number: 2018-068 
PI Name: Whitehead, Shawn N 
AUP Title: Exosome delivery of biologics to mice Approval Date: 07/01/2018  
Official Notice of Animal Care Committee (ACC) Approval:  
Your new Animal Use Protocol (AUP) 2018-068:1: entitled " Exosome delivery of biologics to 
mice" has been APPROVED by the Animal Care Committee of the University Council on 
Animal Care. This approval, although valid for up to four years, is subject to annual Protocol 
Renewal. 
 
Submitted by: Copeman, Laura 
on behalf of the Animal Care Committee University Council on Animal Care  
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